WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

Get full text

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. by Maria Kalyuga, David Gallego-Ortega, Heather J Lee, Daniel L Roden, Mark J Cowley, C Elizabeth Caldon, Andrew Stone, Stephanie L Allerdice, Fatima Valdes-Mora, Rosalind Launchbury, Aaron L Statham, Nicola Armstrong, M Chehani Alles, Adelaide Young, Andrea Egger, Wendy Au, Catherine L Piggin, Cara J Evans, Anita Ledger, Tilman Brummer, Samantha R Oakes, Warren Kaplan, Julia M W Gee, Robert I Nicholson, Robert L Sutherland, Alexander Swarbrick, Matthew J Naylor, Susan J Clark, Jason S Carroll, Christopher J Ormandy

Get full text